Arrest van Europese Hof van Justitie d.d. 21 juni 2017: Vaccin kan ziekte veroorzaken.

22-06-2017 17:01

Het arrest werd gewezen waarbij een verklaring van recht werd gegeven onder beantwoording van prejudiciële vragen. Het verzoek om een prejudiciële beslissing betreft de uitlegging van artikel 4 van richtlijn 85/374/EEG van de Raad van 25 juli 1985 betreffende de onderlinge aanpassing van de wettelijke en bestuursrechtelijke bepalingen der lidstaten inzake de aansprakelijkheid voor producten met gebreken (PB 1985, L 210, blz. 29).

 

Ditverzoek is ingediend in het kader van een geding tussen enerzijds N., L. en C. W (hierna: „W e.a.”), optredend in hun eigen naam en als erfgenamen van J. W, en anderzijds Sanofi Pasteur MSD SNC (hierna: „Sanofi Pasteur”), de Caisse primaire d’assurance maladie des Hauts-de-Seine (ziekenfonds van het departement Hauts-de-Seine, Frankrijk) en Carpimko, een zelfstandig pensioen- en voorzorgsfonds, betreffende de eventuele aansprakelijkheid van Sanofi Pasteur wegens een vermeend gebrek van het door haar geproduceerde vaccin.

 

Onderstaand het persbericht en het arrest.

 

Where there is a lack of scientific consensus, the proof of the defect of the vaccine

and of a causal link between the defect and the damage suffered may be made out

by serious, specific and consistent evidence

The temporal proximity between the administering of a vaccine and the occurrence of a disease,

the lack of personal and familial history of the person vaccinated and the existence of a significant

number of reported cases of the disease occurring following such vaccines being administered

may, where applicable, constitute sufficient evidence to make out such proof

Between the end of 1998 and the middle of 1999 Mr J. W was vaccinated against hepatitis B using

a vaccine produced by Sanofi Pasteur. In August 1999, Mr W began to present with various

troubles, which led to a diagnosis of multiple sclerosis in November 2000. Mr W died in 2011.

Earlier, in 2006, he and his family had brought legal proceedings against Sanofi Pasteur to obtain

compensation for the damage they claim Mr W suffered due to the vaccine.

The case was sent before the cour d’appel de Paris (Court of Appeal, Paris, France), which

observed, inter alia, that there was no scientific consensus supporting a causal relationship

between the vaccination against hepatitis B and the occurrence of multiple sclerosis. It held that no

such causal link had been demonstrated and dismissed the action.

The French Cour de cassation (Court of Cassation), before which an appeal against the judgment

of the Cour d’appel de Paris was brought, asks the Court of Justice whether, despite there being

no scientific consensus and given that, under the EU directive on liability for defective products, 1

the injured person is required to prove the damage, the defect and the causal relationship, the

court may base itself on serious, specific and consistent evidence enabling it to conclude that there

is a causal link between the defect in a vaccine and that there is a causal link between the vaccine

and the disease. Reference has been made in particular to Mr W’s previous excellent state of

health, the lack of family antecedents and the close temporal connection between the vaccination

and the appearance of the disease.

In today’s judgment, the Court holds that evidentiary rules allowing the court, where there is not

certain and irrefutable evidence, to conclude that there is a defect in a vaccine and a causal link

between the defect and a disease on the basis of a set of evidence the seriousness, specificity and

consistency of which allows it to consider, with a sufficiently high degree of probability, that such a

conclusion corresponds to the reality of the situation, are compatible with the Directive. Such

evidentiary rules do not bring about a reversal of the burden of proof which it is for the victim to

discharge, since that system places the burden on the victim to prove the various elements of his

case which, taken together, will provide the court hearing the case with a basis for its conclusion as

to the existence of a defect in the vaccine and a causal link between that defect and the damage

suffered.

Moreover, excluding any method of proof other than certain proof based on medical research,

could make it excessively difficult in many situations or, where it is common ground that medical

research neither confirms nor rules out the existence of a causal link, impossible to establish

 

1 Council Directive 85/374/EEC of 25 July 1985 on the approximation of the laws, regulations and administrative

provisions of the Member States concerning liability for defective products (OJ 1985, L 210, p. 29).

www.curia.europa.eu

producer liability, thereby undermining the effectiveness of the Directive and its objectives, which

are to protect consumer health and safety and ensure a fair apportionment between the injured

person and the producer of the risks inherent in modern technological production.

The Court nevertheless adds that national courts must ensure that the evidence adduced is

sufficiently serious, specific and consistent to warrant the conclusion that, having regard also to the

evidence produced and the arguments put forward by the producer, a defect in the product

appears to be the most plausible explanation for the occurrence of the damage. National courts

must also safeguard their own freedom of assessment in determining whether such proof has been

made out to the requisite legal standard, until such time as they consider themselves in a position

to draw a definitive conclusion on the matter.

In the present case, the Court considers that the temporal proximity between the administering of a

vaccine and the occurrence of a disease, the lack of personal and familial history of that disease,

together with the existence of a significant number of reported cases of the disease occurring

following such vaccines being administered, appears on the face of it to constitute evidence which,

taken together, may lead a national court to consider that a victim has discharged his burden of

proof. That could be the case inter alia where that evidence leads the court to consider, first, that

the administering of the vaccine is the most plausible explanation for the occurrence of the disease

and, second, that the vaccine therefore does not offer the safety that one is entitled to expect.

The Court adds that it is not possible for the national legislature or the national courts to introduce

a method of proof under which the existence of a causal link between the defect attributed to a

vaccine and the damage suffered by the victim will automatically be established when certain

predetermined causation-related factual evidence is presented, as that would have the

consequence of the burden of proof provided for in the Directive being undermined.

 

 

NOTE: A reference for a preliminary ruling allows the courts and tribunals of the Member States, in disputes

which have been brought before them, to refer questions to the Court of Justice about the interpretation of

European Union law or the validity of a European Union act. The Court of Justice does not decide the

dispute itself. It is for the national court or tribunal to dispose of the case in accordance with the Court’s

decision, which is similarly binding on other national courts or tribunals before which a similar issue is raised.

 

Bron: Persbericht No 66/2017  https://curia.europa.eu/jcms/upload/docs/application/pdf/2017-06/cp170066en.pdf

 

Lees de uitspraak hier onderstaand.

https://curia.europa.eu/juris/document/document.jsf;jsessionid=9ea7d0f130d5e24e199bd6444d36bd7ae499dddfdc5d.e34KaxiLc3eQc40LaxqMbN4PaxqPe0?text=&docid=192054&pageIndex=0&doclang=nl&mode=req&dir=&occ=first&part=1&cid=400116

 

================================================================================

Opm. EMLS: Op de website van het samenwerkingsverband STOPUMTS.NL (www.stopumts.nl) wordt eveneens naar het arrest verwezen

================================================================================

EMLS 

Utrecht / Haaksbergen, 22 juni 2017